Economy

Pfizer Reports Fourth-Quarter Earnings Beat and Advances Monthly Obesity Injection

Illustration for: Pfizer Reports Fourth-Quarter Earnings Beat and Advances Monthly Obesity Injection
AI-generated illustration. Visual interpretation does not represent real individuals or scenes.

Feb 3, 2026

THE BARE STORY

Pfizer reported fourth-quarter financial results on Tuesday that exceeded analyst expectations, despite posting a net loss of $1.65 billion. The pharmaceutical company announced revenue of $17.56 billion, a decrease of approximately 1% compared to the same period the previous year. Management attributed the revenue decline primarily to lower demand for its Covid-19 vaccine and antiviral pill, Paxlovid. While adjusted earnings per share reached 66 cents, the net loss marked a shift from the net income recorded a year prior.

Alongside its earnings, Pfizer released data from a mid-stage trial of its experimental obesity drug, PF'3944. The company stated that the ultra-long-acting GLP-1 injection, acquired through the purchase of biotech firm Metsera, resulted in up to 12.3% weight loss by week 28. According to the trial results, patients who transitioned from weekly to monthly doses did not experience a weight loss plateau. Pfizer indicated that it plans to advance 10 phase three trials for the injection this year, positioning it as a potential monthly treatment option.

The company reaffirmed its financial guidance for 2026, projecting adjusted profits between $2.80 and $3.00 per share. Pfizer noted that this outlook factors in anticipated sales declines from products losing market exclusivity and the impact of a drug pricing agreement with President Donald Trump. The company stated the deal involves providing deep discounts to Medicaid and guaranteed "most-favored-nation" pricing for new drugs in exchange for a three-year exemption from tariffs. Additionally, Pfizer is proceeding with initiatives to cut costs by approximately $7.7 billion by the end of 2027.

Same Facts. Different Perspectives.

Two AI models. Two viewpoints. One factual foundation.

Perspective by Claude

• Strong pipeline progress The company’s advancement of its experimental obesity drug, PF'3944, represents a significant opportunity for future growth. Data from the mid-stage trial showed up to 12.3% weight loss, and the ability to transition patients to monthly dosing without hitting a plateau positions the drug as a viable monthly treatment option. Pfizer plans to capitalize on this by advancing 10 phase three trials this year.

• Resilient financial performance Despite the expected decline in demand for Covid-19 products, the company demonstrated financial resilience by exceeding analyst expectations for the fourth quarter. Adjusted earnings per share remained solid at 66 cents, and management felt confident enough to reaffirm its profit guidance for 2026, projecting adjusted profits between $2.80 and $3.00 per share.

• Strategic cost and trade management Management is taking active steps to secure the company's financial future through significant efficiency measures and strategic agreements. Pfizer is proceeding with initiatives to cut costs by roughly $7.7 billion by 2027. Furthermore, the company has secured a three-year exemption from tariffs through a deal with President Trump, mitigating potential trade risks.

How it may affect me

As a U.S. reader:

• Patients seeking weight loss treatments may eventually have access to a monthly injection option as Pfizer moves its experimental drug, which showed significant efficacy, into final testing stages.

• Medicaid recipients could benefit from deep discounts on medications following a negotiated deal between Pfizer and President Trump that includes specific pricing concessions.

• New drugs brought to market might be subject to "most-favored-nation" pricing guarantees, potentially limiting the costs consumers face for future innovative treatments.

• The prices of Pfizer products are unlikely to be affected by import levies for the next three years, as the company secured an exemption from tariffs.

Read the story at

Note: All TheBareNews content is AI-generated. For additional context, reporting, and updates, you are invited to explore the news outlets linked above.